Sacituzumab govitecan (SG) in patients with advanced endometrial cancer
Raffaele Colombo shared a post on X:
“Sacituzumab govitecan (SG) in patients with advanced endometrial cancer (from TROPiCS-03) TROP2 expression didn’t correlate with efficacy, and PFS was similar between subgroups, suggesting that response to SG is observed regardless of the level of TROP2.”
Authors: Alessandro D. Santin, Bradley R. Corr, Alexander Spira, Lyndsay Willmott, James Butrynski, Ka Yu Tse, Jilpa Patel, Sabeen Mekan, Tia Wu, Kai-Wen Lin, Peiwen Kuo and Ecaterina E. Dumbrava.
Source: Raffaele Colombo/X
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
